Expertise in
33
conditions

Dr. Daniel C. Bowers

Hematology | Oncology
Children's Medical Center/Children's Health
1935 Medical District Dr, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
33
conditions
Children's Medical Center/Children's Health
1935 Medical District Dr, 
Dallas, TX 

Overview

Daniel Bowers is a Hematologist and an Oncologist practicing medicine in Dallas, Texas.

Dr. Bowers is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Posterior Fossa Tumor, Ependymoma, Medulloblastoma, and Brain Tumor.

He is actively involved in clinical research, co-authoring 78 peer reviewed articles and participating in 9 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in TX

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

Children's Medical Center/Children's Health
1935 Medical District Dr, Dallas, TX 75235

Additional Areas of Focus

Dr. Bowers has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Childhood Cancer Survivor Study
Childhood Cancer Survivor Study
Enrollment Status: Recruiting
Publish Date: June 17, 2026
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: October 06, 2026
Intervention Type: Drug, Radiation
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate
Study Phase: Phase 2
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
A Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Selumetinib, Vinblastine
Study Phase: Phase 3
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Other, Radiation
Study Drugs: Cyclophosphamide, Cisplatin, Vincristine, Vismodegib, Pemetrexed, Gemcitabine
Study Phase: Phase 2
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Enrollment Status: Approved_for_marketing
Publish Date: August 20, 2025
Intervention Type: Drug
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial
Enrollment Status: Completed
Publish Date: April 23, 2025
Intervention Type: Other, Drug
Study Drug: Carvedilol
Study Phase: Phase 2
Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma
Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma
Enrollment Status: Completed
Publish Date: May 08, 2024
Intervention Type: Drug
Study Drug: Everolimus
Study Phase: Phase 2
View 8 Less Clinical Trials

78 Total Publications

Magic state cultivation on a superconducting quantum processor.
Magic state cultivation on a superconducting quantum processor.
Journal: Science (New York, N.Y.)
Published: October 15, 2026
Similar Doctors
Expertise in
38
conditions
Dr. Farrukh T. Awan
Hematology | Oncology
Expertise in
38
conditions
Dr. Farrukh T. Awan
Hematology | Oncology
Referral may be required

UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center

2201 Inwood Rd, 
Dallas, TX 
 (0.8 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Farrukh Awan is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Awan is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

UT Southwestern Zale Lipshy Pavilion William P Clements JR University Hospital

6201 Harry Hines Blvd, 
Dallas, TX 
 (0.9 miles away)
214-645-8300
Languages Spoken:
English
See accepted insurances

David Gerber is an Oncologist practicing medicine in Dallas, Texas. Dr. Gerber is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

Office

2201 Inwood Rd, 
Dallas, TX 
 (0.8 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hans Hammers is an Oncologist practicing medicine in Dallas, Texas. Dr. Hammers is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Wilms Tumor, Nephrectomy, and Thrombectomy.

Expertise in
14
conditions
Expertise in
14
conditions
Referral required
Before you request

Texas Oncology, P.A.

3410 Worth Street, Suite 400, 
Dallas, TX 
 (3.7 miles away)
214-370-1000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. O'Shaughnessy is a Medical Oncologist that focuses on breast cancer prevention and treatment. She founded The School of Breast Oncology, a program providing a curriculum-based program focused exclusively on breast cancer clinical management. Dr. O'Shaughnessy attended medical school at Yale University School of Medicine in New Haven, CT. She then completed her Internal Medicine residency at Massachusetts General Hospital in Boston, MA and a Medical Oncology fellowship at National Cancer Institute in Bethesda, MD. She is co-chair of Breast Cancer Research, chair of Breast Cancer Prevention Research at Baylor Charles A. Sammons Cancer Center and a member of the Scientific Advisory Board for US Oncology Research Network. Dr. O'shaughnessy is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Inflammatory Breast Cancer, and Tissue Biopsy. Dr. O'shaughnessy is board certified in Medical Oncology- American Board Of Internal Medicine, Medical Oncology- American Board Of Internal Med/Medical Oncology, Internal Medicine- American Board Of Internal Med, and Internal Medicine- American Board Of Internal Medicine. Dr. O'shaughnessy is currently accepting new patients.

Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required

UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center

2201 Inwood Rd, 
Dallas, TX 
 (0.8 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Robert Collins is an Oncologist practicing medicine in Dallas, Texas. Dr. Collins is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (0.2 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Larry Anderson is an Oncologist practicing medicine in Dallas, Texas. Dr. Anderson is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Plasmacytoma, Smoldering Multiple Myeloma, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Daniel C. Bowers

How do I make an appointment with Dr. Daniel C. Bowers?

You can book an appointment with Dr. Daniel C. Bowers by calling their office at 214-456-2382. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel C. Bowers a top-rated expert for Posterior Fossa Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel C. Bowers is classified as an Elite expert for Posterior Fossa Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel C. Bowers specialize in?

While Dr. Daniel C. Bowers is a Hematology, they have specific expertise in Posterior Fossa Tumor, Ependymoma, and Medulloblastoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Daniel C. Bowers participate in research or clinical trials?

Yes. Dr. Daniel C. Bowers has published 78 articles and abstracts on conditions like Posterior Fossa Tumor. You can view a list of Dr. Daniel C. Bowers's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel C. Bowers accept my insurance?

Dr. Daniel C. Bowers accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 214-456-2382 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bowers's expertise for a condition
ConditionClose
View All 23 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile